Insights Into GoodRx (GDRX) Q4: Wall Street Projections for Key Metrics

Wall Street analysts forecast that GoodRx Holdings, Inc. (GDRX) will report quarterly earnings of $0.09 per share in its upcoming release, pointing to a year-over-year increase of 12.5%. It is anticipated that revenues will amount to $199.81 million, exhibiting an increase of 1.6% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.That said, let's delve into the average estimates of some GoodRx metrics that Wall Street analysts commonly model and monitor.The consensus estimate for 'Revenue- Prescription transactions' stands at $143.21 million. The estimate indicates a change of -0.5% from the prior-year quarter.The consensus among analysts is that 'Revenue- Other' will reach $5.19 million. The estimate points to a change of -0.7% from the year-ago quarter.It is projected by analysts that the 'Revenue- Pharma Manufacturer Solutions' will reach $29.57 million. The estimate points to a change of +21.2% from the year-ago quarter.Analysts' assessment points toward 'Revenue- Subscription' reaching $21.83 million. The estimate points to a change of -5.7% from the year-ago quarter.Analysts predict that the 'Monthly Active Consumers' will reach 7. Compared to the current estimate, the company reported 6 in the same quarter of the previous year.The combined assessment of analysts suggests that 'Subscribers plans' will likely reach 702. The estimate is in contrast to the year-ago figure of 884.View all Key Company Metrics for GoodRx here>>>Over the past month, GoodRx shares have recorded returns of -0.2% versus the Zacks S&P 500 composite's -1.8% change. Based on its Zacks Rank #3 (Hold), GDRX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GoodRx Holdings, Inc. (GDRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks